# Health Innovation Fund

> Health Innovation Fund is a VC fund in Oakland backing Health Care and Medical. See 8 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Oakland, United States
- Total investments: 8
- Last investment: Jan 2021
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/showcase/chcf-health-innovation-fund
- X (Twitter): https://twitter.com/chcfinnovations
- Website: http://www.chcf.org

Health Innovation Fund is a London-based venture capital fund that invests in innovative healthcare-related projects.

## Contacts

5 contacts available for Health Innovation Fund. Shizune tracks 2 team members at Health Innovation Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/health-innovation-fund?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 75% |
| Medical | 5 | 63% |
| Biotechnology | 3 | 38% |
| Hospital | 2 | 25% |
| Medical Device | 2 | 25% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 38% |
| Series B | 3 | 38% |
| Series A | 1 | 13% |
| Funding Round | 1 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 38% |
| The Netherlands | 3 | 38% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Dick Sietses | Partner; Managing Partner | 5 | https://shizune.co/investors/profile/dick-sietses |
| Sandra Hernández | President, Chief Executive Officer and Board Member | 0 | https://shizune.co/investors/profile/sandra-hern%C3%A1ndez |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Obatala Sciences | Obatala Sciences, a fat-on-a-chip biotechnology company, was incorporated to reduce the $2 Trillion economic burden associated with Obesity and Diabetes. Obatala is revolutionizing our view of body fat by highlighting its importance as a functional organ, and a regulator of body health and disease. | $1.1M | Seed | Jan 22, 2021 |  |
| Prolira makers of DeltaScan® | Prolira is committed to enabling early and effective treatment of acute encephalopathy and delirium. Every year, 20 million patients are at risk of acute brain failure in EU and US hospitals, which leads to long-term cognitive impairment, extended hospital stays, and increased healthcare costs.Prolira’s DeltaScan® Brain State Monitor is theworld’s first EEG bedside device with a validated proprietary algorithm to support clinicians in their quest to optimize patient recovery. | $1.8M | Seed | Nov 01, 2018 |  |
| FABPulous | FABPulous is an innovative healthcare company which develops and markets solutions for diagnostics in primary care and emergency medicine.FABPulous is a company based in The Netherlands. It was spun out of Maastricht University at the end of 2008. In December 2009 FABPulous closed a first equity financing round co-led by Thuja Capital, HealthInnovations, Limburg Ventures and NV Industriebank LIOF.The company has developed a technology that allows a simple, robust and ultra-rapid diluted plasma preparation from a drop of blood. This offers great advantages in the point-of-care (POC) and home testing setting, over current technology. It concerns a disposable plasma preparation device that can be integrated with many IVD detection platforms, such lateral flow devices. The first product application under development by FABPulous is a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), to aid in the first-line diagnosis of acute myocardial infarction. |  |  | Oct 17, 2017 |  |
| CirraGroup | CirraGroup is an innovator in medical debt settlement technology to resolve billions in bad debt. Our solutions support the financial needs of a wide array of healthcare providers as well as revenue cycle management vendors. Our two HIPPA compliant, cloud-based platforms help patients resolve medical debts and providers improve patient-to-providercash flows. The company’s patented healthcare cooperative database uses an innovative crowdsourcing platform in which subscribing providers contribute and share outstanding patient account data with each other to make smarter credit decisions at the point-of-service. Patients can access and settle those outstanding accounts reported in the database from a secure portal and clearinghouse that incentivizes them to pay. | $500K | Series B | Jul 12, 2016 |  |
| Nightbalance | NightBalance B.V. is an enterprise which was started by TU Delft alumni. In 2007 the research into improved position therapy aids began at the Delft University of Technology. NightBalance was founded in 2009 based on the research at the university in order to further develop the Sleep Position Trainer. |  | Series B | Jul 05, 2016 |  |
| DirectDerm | DirectDerm is to allow medical providers the ability to access immediate consultative services with a top-quality US board-certified dermatologist for any of their patients' skin related medical problems. | $240K | Seed | Dec 06, 2011 |  |
| FABPulous | FABPulous is an innovative healthcare company which develops and markets solutions for diagnostics in primary care and emergency medicine.FABPulous is a company based in The Netherlands. It was spun out of Maastricht University at the end of 2008. In December 2009 FABPulous closed a first equity financing round co-led by Thuja Capital, HealthInnovations, Limburg Ventures and NV Industriebank LIOF.The company has developed a technology that allows a simple, robust and ultra-rapid diluted plasma preparation from a drop of blood. This offers great advantages in the point-of-care (POC) and home testing setting, over current technology. It concerns a disposable plasma preparation device that can be integrated with many IVD detection platforms, such lateral flow devices. The first product application under development by FABPulous is a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), to aid in the first-line diagnosis of acute myocardial infarction. |  | Series A | Jan 11, 2010 |  |
| FABPulous | FABPulous is an innovative healthcare company which develops and markets solutions for diagnostics in primary care and emergency medicine.FABPulous is a company based in The Netherlands. It was spun out of Maastricht University at the end of 2008. In December 2009 FABPulous closed a first equity financing round co-led by Thuja Capital, HealthInnovations, Limburg Ventures and NV Industriebank LIOF.The company has developed a technology that allows a simple, robust and ultra-rapid diluted plasma preparation from a drop of blood. This offers great advantages in the point-of-care (POC) and home testing setting, over current technology. It concerns a disposable plasma preparation device that can be integrated with many IVD detection platforms, such lateral flow devices. The first product application under development by FABPulous is a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), to aid in the first-line diagnosis of acute myocardial infarction. | $1.9M | Series B |  |  |

8 of 8 investments shown.

## Co-investors
- [Thuja Capital](https://shizune.co/investors/profile/thuja-capital) — VC Fund, 3 deals together
- [Limburg Ventures](https://shizune.co/investors/profile/limburg-ventures) — VC Fund, 2 deals together
- [Elevate Capital](https://shizune.co/investors/profile/elevate-capital) — VC Fund, 1 deal together
- [Gilde Healthcare](https://shizune.co/investors/profile/gilde-healthcare-partners) — VC Fund, 1 deal together
- [Holland Capital](https://shizune.co/investors/profile/holland-venture) — VC Fund, 1 deal together
- [Inkef](https://shizune.co/investors/profile/inkef-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Health Innovation Fund invest in?

Health Innovation Fund invests primarily in Health Care, Medical and Biotechnology startups, most often at Seed and Series B stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Health Innovation Fund?

Public channels for Health Innovation Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Health Innovation Fund?

The team at Health Innovation Fund includes Dick Sietses (Partner; Managing Partner) and Sandra Hernández (President, Chief Executive Officer and Board Member). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co